不同深度镇静方案用于成人纤维支气管镜检查的效果比较

注册号:

Registration number:

ChiCTR2500115529 

最近更新日期:

Date of Last Refreshed on:

2025-12-28 20:56:24 

注册时间:

Date of Registration:

2025-12-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

不同深度镇静方案用于成人纤维支气管镜检查的效果比较

Public title:

Comparison of the effects of different deep sedation regimens for adult flexible bronchoscopy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

非插管高阿片化镇静麻醉技术用于纤维支气管镜检查的可行性研究

Scientific title:

Feasibility study on non-intubated sedation with high-opioid for flexible bronchoscopy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曹云飞 

研究负责人:

曹云飞 

Applicant:

Yunfei Cao 

Study leader:

Yunfei Cao 

申请注册联系人电话:

Applicant telephone:

+86 135 0588 6675

研究负责人电话:

Study leader's
telephone:

+86 135 0588 6675

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

caoyunfeicn@sina.com

研究负责人电子邮件:

Study leader's E-mail:

caoyunfeicn@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

宁波市北仑区庐山东路1288号北仑区人民医院住院部三楼手术室

研究负责人通讯地址:

宁波市北仑区庐山东路1288号北仑区人民医院住院部三楼手术室

Applicant address:

Operating Room, 3rd Floor, Inpatient Department, Beilun People's Hospital, 1288 Lushan East Road

Study leader's address:

Operating Room, 3rd Floor, Inpatient Department, Beilun People's Hospital, 1288 Lushan East Road

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宁波市北仑区人民医院

Applicant's institution:

Beilun District People's Hospital of Ningbo

研究负责人所在单位:

宁波市北仑区人民医院

Affiliation of the Leader:

Beilun District People's Hospital of Ningbo

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024科审第(30)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁波市北仑区人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Beilun District People's Hospital, Ningbo

伦理委员会批准日期:

Date of approved by ethic committee:

2024-02-15 00:00:00

伦理委员会联系人:

马海芬

Contact Name of the ethic committee:

Haifen Ma

伦理委员会联系地址:

浙江省宁波市北仑区庐山东路1288号北仑区人民医院科教科

Contact Address of the ethic committee:

Department of Science and Education, Beilun District People's Hospital, 1288 Lushan East Road, Beilun District, Ningbo City, Zhejiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 574 8677 6057

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宁波市北仑区人民医院

Primary sponsor:

Beilun District People's Hospital of Ningbo

研究实施负责(组长)单位地址:

浙江省宁波市北仑区庐山东路1288号北仑区人民医院

Primary sponsor's address:

Beilun District People's Hospital, 1288 Lushan East Road, Beilun District, Ningbo City, Zhejiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang Province

City:

单位(医院):

宁波市北仑区人民医院

具体地址:

浙江省宁波市北仑区庐山东路1288号北仑区人民医院

Institution
hospital:

Beilun District People's Hospital of Ningbo

Address:

Beilun District People's Hospital, 1288 Lushan East Road, Beilun District, Ningbo City, Zhejiang Province

经费或物资来源:

浙江省医药卫生科研项目(2024XY036)

Source(s) of funding:

The medical and health research project of Zhejiang province(2024XY036)

研究疾病:

支气管、肺、胸腔等疾病  

Target disease:

Bronchus, lung, chest and other diseases

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

建立一套适合成年患者的安全性高、效果确切、临床可推广的无痛FB检查临床实践新方案,并达到镇咳镇静效果好、副作用少、周转快速的舒适化医疗要求和舒适医疗惠民生的目标。  

Objectives of Study:

To establish a new clinical practice regime of painless flexible bronchoscopy suitable for adult patients, which is highly safe, effective and clinically promotable, and achieve the requirements of comfortable medical care with good antitussive and sedative effects, few side effects and fast turnover.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.不符合纳入标准者; 2.合并心血管、肝肾、造血系统、神经系统或全身性疾病的患者; 3.合并酗酒史或长期使用阿片类药物或镇静药物的患者; 4.有严重认知障碍患者; 5.合并哮喘史的患者; 6.孕妇及哺乳期妇。

Exclusion criteria:

1.Those who do not meet the inclusion criteria; 2.Patients with concurrent cardiovascular, liver and kidney, hematopoietic system, nervous system or systemic diseases; 3.Patients with a history of alcohol abuse or those who have been using opioids or sedatives for a long time; 4.Patients with severe cognitive impairment; 5.Patients with a history of asthma; 6.Pregnant and lactating women.

研究实施时间:

Study execute time:

From 2024-04-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

丙泊酚舒芬太尼组合方案(PS组)

样本量:

70

Group:

Regimen combination with propofol and sufentanil (PS group)

Sample size:

干预措施:

高流量湿化氧疗(50L/min)+镇静方案[舒芬太尼1g/kg,丙泊酚1-2mg/kg滴定至目标镇静深度[MOAA/S(Modified Observers Assessment of Alertness/Sedation)评分≦1]

干预措施代码:

Intervention:

High flow humidifying oxygen therapy (45L/min) + sedation program [Sufentanil 1g/kg, propofol 1-2mg/kg titrated to the target sedation depth, that is, MOAA/S(Modified Observers Assessment of Alertness/Sedation)≦1

Intervention code:

组别:

咪达唑仑阿芬太尼组合方案(MA组)

样本量:

70

Group:

Regimen combination with midazolam and afentanil (MA group)

Sample size:

干预措施:

高流量湿化氧疗(50L/min)+咪达唑仑0.045mg/kg,间隔1min后给予阿芬太尼23mg/kg,如未达到目标镇静深度[MOAA/S评分≦1],则予追加丙泊酚并滴定至目标镇静深度。

干预措施代码:

Intervention:

High-flow humidified oxygen therapy (50L/min) + midazolam 0.045mg/kg, and 23mg/kg of afentanil were given at an interval of 1min. If the target sedation depth(MOAA/S≦1) was not reached. Propofol was added and titrated to the target sedation depth.

Intervention code:

组别:

瑞马唑仑阿芬太尼组合方案(RA组)

样本量:

70

Group:

Regimen combination with remimazolam and afentanil (RA group)

Sample size:

干预措施:

高流量湿化氧疗(50L/min)+瑞马唑仑0.2mg/kg,间隔1min后给予阿芬太尼23mg/kg,如未达到目标镇静深度[MOAA/S评分≦1],则予追加瑞马唑仑并滴定至目标镇静深度。

干预措施代码:

Intervention:

High-flow moist oxygen therapy (50L/min) +Remimazolam 0.2mg/kg, and 23mg/kg of afentanil were given at an interval of 1min. If the target sedation depth(epth(MOAA/S≦1) was not reached. Remimazolam was added and titrated to the target sedation depth.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang Province

City:

单位(医院):

宁波市北仑区人民医院 

单位级别:

三级 

Institution
hospital:

Beilun District People's Hospital of Ningbo

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

VAS 呛咳评分

指标类型:

主要指标

Outcome:

VAS choke score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期血流动力学

指标类型:

次要指标

Outcome:

Perioperative hemodynamics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低氧发生率

指标类型:

次要指标

Outcome:

Hypoxia incidence

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

复苏时间

指标类型:

次要指标

Outcome:

Patient resuscitation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者满意度及手术医师满意度

指标类型:

次要指标

Outcome:

Patient satisfaction and Surgeon satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后不良反应

指标类型:

次要指标

Outcome:

Postoperative adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后睡眠评估

指标类型:

次要指标

Outcome:

Postoperative sleep assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

简单随机,由助手按随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Table of random numbers by assistant

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲,对研究参与者设盲

Blinding:

Single-blind, blinding of study participants

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后,通过ResMan(www.medresman.org.cn)方式共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the end of the study, it was shared by ResMan (www.medresman.org.cn).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-28 20:56:09